More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
A new two-year study is focused on the potential of using commercially available fitness trackers to identify patients who may face an increased risk of CVD.
Multiple studies in recent years have linked poor air quality to significant cardiac risks. Air filters, however, have shown potential to help combat these risks.
The excessive use of electronic devices is associated with significant health risks for young children and adolescents. In fact, too much screen time may impact the body in ways that last well into adulthood.
Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.
